Swipe Left For English News
中国上海 | 英国伦敦,
2023年11月21日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）与专注于基于有效载荷NMTi研发新型抗体偶联药物（ADC）的英国生物技术公司Myricx Bio（以下简称Myricx）今日共同宣布达成一项许可协议，Myricx将获得一款基于药明生物一体化平台发现的一款抗体的独家权利。
根据协议条款，Myricx将通过其NMTi有效载荷平台，基于该抗体研发全球首创（first-in-class）的ADC。相比常用的效载荷类型，NMTi有效载荷平台具有高度差异化的微管和拓扑异构酶抑制剂等。Myricx计划在难治性实体瘤中推进该ADC产品的临床前和临床开发。药明生物将获得一笔预付款，并有资格获得开发和商业化里程碑付款，以及净销售分成。
陈智胜博士
首席执行官
药明生物
此次与Myricx达成许可协议是药明生物一体化抗体技术平台的又一力证，也再次凸显了公司独特CRDMO商业模式中‘R’（研究服务）的优势。我们期待赋能全球客户研发更多first-in-class和best-in-class的生物药，惠及广大患者。
Robin Carr 博士
首席执行官
Myricx公司
我们很高兴与全球领先的生物药CRDMO公司药明生物达成这一协议。我们相信这款先进的抗体将与基于NMTi的创新有效载荷强强联合，开发出在实体瘤中具有显著临床差异化优势的ADC。根据NMTi积极临床前数据显示，NMTi-ADCs在不同的癌症靶标中表现出了高度分化的作用机制、出色的疗效和良好的耐受性。
药明生物通过行业领先的技术平台和全面的研究能力，提供从概念到临床前候选药物的全方位端到端和模块化的生物药发现服务。公司用于发现、筛选、优化和鉴定抗体与生物药的技术平台包括杂交瘤技术、单B细胞克隆技术、噬菌体展示和酵母展示技术、全人天然抗体文库和VHH免疫文库、人抗体转基因鼠平台（与OmniAb®和Alloy Therapeutics）、双/多特异性抗体（WuXiBody™和SDarBody™等），以及其他生物药优化技术。公司各种的生物材料研发能力和检测能力为技术平台提供重要的支撑。
如果您对药明生物新药开发和服务感兴趣，
欢迎扫描下方二维码留下您的联系方式
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年6月底，药明生物帮助客户研发和生产的综合项目高达621个，其中包括22个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
关于Myricx Bio
Myricx Bio（简称Myricx）是一家英国生物技术公司，专注于基于有效载荷N-肉豆蔻酰转移酶（NMT）抑制剂研发新型抗体偶联药物 （ADCs），用于癌症治疗。
NMT是一种在决定癌细胞存活关键的系列蛋白靶标上增加了特异性脂质修饰的酶。Myricx 正在基于其NMT抑制剂（NMTi）有效载荷技术平台，推进ADC产品线研发，以解决肿瘤学领域严重未满足的临床需求，并已在多种实体瘤相关抗原和癌症临床前研究中表现出优异的疗效和安全性。
Myricx总部位于伦敦，由伦敦帝国理工学院和弗朗西斯·克里克研究所孵化，投资来自Sofinnova Partners和Brandon Capital Partners。
如需更多信息，请浏览：www.myricxbio.com
药明生物
媒体关系 PR@wuxibiologics.com
业务垂询 info@wuxibiologics.com
Myricx Bio
公司问询
Dr Robin Carr, CEO, Myricx Bio, info@myricxbio.com
媒体问询
Sue Charles, Charles Consultants, sue@charles-consultants.com, +44 (0)7986 726585
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
Shanghai, CHINA and London, UK,
November 21, 2023
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Myricx Bio ("Myricx"), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announced that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio's integrated technology platforms.
Under the terms of the agreement, Myricx will develop the antibody into a first-in-class ADC based on its NMTi payload platform, which has a highly differentiated profile over standard payload classes, including microtubule and topoisomerase inhibitors. Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours. WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales.
Dr. Chris Chen
CEO
WuXi Biologics
This license agreement with Myricx is another testament of our proprietary integrated platform and the 'R' in our CRDMO business model. We are looking forward to enabling global clients to develop more first-in-class and best-in-class biologics drugs for the benefits of patients worldwide.
Dr. Robin Carr
CEO
Myricx
We are delighted to have reached this agreement with WuXi Bio, one of the top biologics CRDMOs globally. We believe that combining this leading antibody with our novel NMTi-based payload will create an ADC with significant clinical differentiation in solid tumours. Based on our positive preclinical data we believe NMTi-ADCs offer a highly differentiated mechanism of action, superb efficacy and good tolerability across different cancer targets.
WuXi Biologics offers a full spectrum of end-to-end and modular discovery services from idea to preclinical candidate identification using industry leading technology platforms and comprehensive discovery capabilities. Its discovery technology platforms for the generation, characterization, engineering, optimization and selection of novel antibody and biologic therapeutics include hybridoma technology, single B cell cloning technology, phage display and yeast display technology, immune and synthetic human scFv and VHH libraries, the human IgG transgenic platforms through OmniAb® and Alloy partnership, bispecific antibody platforms represented by the WuXiBody™ and SDarBody™, and other antibody and biologics generation and optimization technologies. All technology platforms are supported by the company's comprehensive research material generation and assay development capabilities.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
About Myricx Bio
Myricx Bio ("Myricx") is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.
NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.
Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.
For more information about Myricx Bio, please visit www.myricxbio.com
Contacts
WuXi Biologics
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
Myricx Bio
At the Company
Dr Robin Carr, CEO, Myricx Bio, info@myricxbio.com
Media Enquiries
Sue Charles, Charles Consultants, sue@charles-consultants.com, +44 (0)7986 726585
注：本信息不构成药明生物的信息披露或投资建议
